We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 21, 2020

Overnight Fasting Before Lapatinib Administration to Breast Cancer Patients Leads to Reduced Toxicity

Cancer Medicine

 

Additional Info

Cancer Medicine
Overnight Fasting Before Lapatinib Administration to Breast Cancer Patients Leads to Reduced Toxicity Compared With Nighttime Dosing: A Retrospective Cohort Study From a Randomized Clinical Trial
Cancer Med 2020 Oct 23;[EPub Ahead of Print], M Tsuda, H Ishiguro, N Toriguchi, N Masuda, H Bando, M Ohgami, M Homma, S Morita, N Yamamoto, K Kuroi, Y Yanagita, T Takano, S Shimizu, M Toi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading